

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5	"5941116"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 12:03
L2	20	"5914116"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 12:05
L3	2	"6548072"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 12:05
L4	11894	retinoid or retinoids	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:10
L5	11894	L4	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:12
L6	3594	genistein or diadzein or glycitin or biocnanin or formononetin or equol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:12
L7	3594	L6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:12
L8	669	L4 and L6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:13
L9	18	"glycyrrretinic acid"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:13
L10	17684	"phosphatidylcholine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:13
L11	1	L9 and L10	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:14

EAST Search History

L12	17701	L9 or L10	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:14
L13	64	L8 and L12	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:15
L14	8290	amsacrine or carbenolone or sphingomyelin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:15
L15	20774	"arachidic acid" or "myristic acid"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:16
L16	27971	L14 or L15	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:17
L17	1275	L4 and L16	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:17
L18	122	L8 and L16	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/12 13:17

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	7	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	26	APR 30	CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS	27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	28	MAY 01	New CAS web site launched
NEWS	29	MAY 08	CA/CAPLUS Indian patent publication number format defined
NEWS	30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	33	MAY 21	CA/CAPLUS enhanced with additional kind codes for German patents
NEWS	34	MAY 22	CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:21:11 ON 12 JUN 2007

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 13:21:30 ON 12 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Jun 2007 VOL 146 ISS 25

FILE LAST UPDATED: 11 Jun 2007 (20070611/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s amsacrine or carbenoxolone or "glycyrrretinic acid" or phosphatidylcholine or shingomyelin or phosphatidyl

944 AMSACRINE

3 AMSACRINES

945 AMSACRINE

(AMSACRINE OR AMSACRINES)

714 CARBENOXOLONE

1 CARBENOXOLONES

714 CARBENOXOLONE

(CARBENOXOLONE OR CARBENOXOLONES)

7 "GLYCYRRETINIC"

4384552 "ACID"

1577490 "ACIDS"

4883603 "ACID"

("ACID" OR "ACIDS")

7 "GLYCYRRETINIC ACID"

("GLYCYRRETINIC" (W) "ACID")

38929 PHOSPHATIDYLCHOLINE

33041 PHOSPHATIDYLCHOLINES

51628 PHOSPHATIDYLCHOLINE

(PHOSPHATIDYLCHOLINE OR PHOSPHATIDYLCHOLINES)

2 SHINGOMYELIN

5007 PHOSPHATIDYL
4 PHOSPHATIDYLS
5010 PHOSPHATIDYL
(PHOSPHATIDYL OR PHOSPHATIDYLS)
L1 56873 AMSACRINE OR CARBENOXOLONE OR "GLYCYRRETTIC ACID" OR PHOSPHATIDYLCHOLINE OR SHINGOMYELIN OR PHOSPHATIDYL

=> s phytoestrogen
1925 PHYTOESTROGEN
2508 PHYTOESTROGENS
L2 2900 PHYTOESTROGEN
(PHYTOESTROGEN OR PHYTOESTROGENS)

=> s L1 and L2
L3 12 L1 AND L2

=> dup rem L3
PROCESSING COMPLETED FOR L3
L4 12 DUP REM L3 (0 DUPLICATES REMOVED)

=> s retinoid or retinol or retinal or retinoic acid
12608 RETINOID
8574 RETINOIDS
15510 RETINOID
(RETINOID OR RETINOIDS)
13352 RETINOL
121 RETINOLS
13371 RETINOL
(RETINOL OR RETINOLS)
32481 RETINAL
404 RETINALS
32516 RETINAL
(RETINAL OR RETINALS)
23469 RETINOIC
2 RETINOICS
23469 RETINOIC
(RETINOIC OR RETINOICS)
4384552 ACID
1577490 ACIDS
4883603 ACID
(ACID OR ACIDS)
23389 RETINOIC ACID
(RETINOIC(W)ACID)
L5 70242 RETINOID OR RETINOL OR RETINAL OR RETINOIC ACID

=> s L3 and L5
L6 1 L3 AND L5

=> s L3 and L1
L7 12 L3 AND L1

=> s L5 and L1
L8 661 L5 AND L1

=> s L5 and L2
L9 37 L5 AND L2

=> d L6 ibib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:388632 CAPLUS
DOCUMENT NUMBER: 125:67813
TITLE: Pharmaceutical compositions containing
phytoestrogens for the treatment of diabetic

INVENTOR(S): male sexual dysfunction
 Shlyankevich, Mark
 PATENT ASSIGNEE(S): Bio-Virus Research Inc., USA
 SOURCE: U.S., 3 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5523087	A	19960604	US 1995-389006	19950215
PRIORITY APPLN. INFO.:			US 1995-389006	19950215

AB A pharmaceutical composition is disclosed for the treatment of diabetic male sexual dysfunction, which comprises: (a) 45 to 60 parts by weight of one or more phytoestrogen compds. calculated as a free aglycon form of isoflavone; (b) 0 to 400, preferably 200 to 300, parts by weight of phosphatidylcholine; (c) 10 to 50 parts by weight of β -sitosterol; (d) 0 to 300, preferably 30 to 100, parts by weight of Damiana leaf dry extract; (e) 0 to 15, preferably 1 to 3 parts by weight of vitamin A; (f) 0 to 250, preferably 20 to 100, parts by weight of vitamin B1; (g) 0 to 300, preferably 50 to 150, parts by weight of vitamin B6; (h) 0 to 100, preferably 10 to 70, parts by weight of vitamin E; (i) 0 to 300, preferably 50 to 200, parts by weight of calcium contained in a biol. acceptable calcium salt; (j) 0 to 750, preferably 300 to 500, parts by weight of magnesium contained in a biol. acceptable magnesium salt; and (k) 0 to 100, preferably 10 to 90 parts by weight of zinc contained in a biol. acceptable zinc salt; in admixt. with a biol. acceptable inert carrier.

=> s skin care or dermatological
 257578 SKIN
 10401 SKINS
 263467 SKIN
 (SKIN OR SKINS)
 54583 CARE
 190 CARES
 54751 CARE
 (CARE OR CARES)
 3198 SKIN CARE
 (SKIN(W)CARE)
 2074 DERMATOLOGICAL
 12 DERMATOLOGICALS
 2084 DERMATOLOGICAL
 (DERMATOLOGICAL OR DERMATOLOGICALS)
 6010 DERMATOL
 6877 DERMATOLOGICAL
 (DERMATOLOGICAL OR DERMATOL)
 L10 9888 SKIN CARE OR DERMATOLOGICAL

=> s L8 and L10
 L11 5 L8 AND L10
 => dup rem L11
 PROCESSING COMPLETED FOR L11
 L12 5 DUP REM L11 (0 DUPLICATES REMOVED)

=> d 1-5 ibib abs L11

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:458900 CAPLUS
 DOCUMENT NUMBER: 146:427847
 TITLE: Topically applied glucosamine sulfate and all its

related, precursor, and derivative compounds significantly increases the skin's natural production of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while phosphatidylcholine is required to replace its deficiency caused by topical dimethylaminoethanol (DMAE)

INVENTOR(S): Jacobs, Eric
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007092469	A1	20070426	US 2006-527334	20060927
PRIORITY APPLN. INFO.:			US 2005-729947P	P 20051026

AB A topical skin rejuvenation preparation comprises (i) about 0.001 to 50% of glucosamine (2-amino-2-deoxy-alpha-D-glucose), a hexosamine (6 carbon amino sugar), including its derivative and precursor compds., glucosamine sulfate, glucosamine hydrochloride, glucose-6-phosphate, acetyl glucosamine, fructose-6-phosphate, and glucosamine-6-phosphate to increase production of hyaluronic acid and collagen and to relieve wrinkles, increase the skin's natural production of hyaluronic acid, reverse the lack of suppleness, hydrate from within, erase spider veins, reduce varicose veins, lighten aging dark blotches ("liver spots"/lentigos, senile lentiginos), decrease acne, and reduce under eye puffiness, (ii) 0.0001 to 50% of dimethylaminoethanol (DMAE) to increase skin muscle tone, and (iii) 0.01 to 30% of phosphatidylcholine to overcome deficiency created by application of DMAE in each cell's production of phosphatidylcholine, whose deficiency damages cell membranes, as well as mitochondrial and lysosome membranes.

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:4769 CAPLUS
DOCUMENT NUMBER: 138:61071
TITLE: Topical compositions containing ethyl linoleate and triethyl citrate
INVENTOR(S): De Paoli Ambrosi, Gianfranco
PATENT ASSIGNEE(S): Italy
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1269991	A2	20030102	EP 2002-425243	20020418
EP 1269991	A3	20040519		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
IT 2001BS0046	A1	20021220	IT 2001-BS46	20010620
PRIORITY APPLN. INFO.:			IT 2001-BS46	A 20010620

AB The present invention relates to a composition for topical use, in particular aimed at skin care and at improving the aesthetic conditions of the same, characterized in that as active ingredient, it contains at least 1 of the active principles selected from Et linoleate and tri-Et citrate, which may be used both individually and in association. When used individually, Et linoleate can be contained in the composition at

1.0-20%. When used individually, tri-Et citrate can be contained at 0.50-30%. When used in association, Et linoleate and tri-Et citrate can be contained at 1.00-40% each. Thus, a formulation contained Staereth-21 2.000, stearate glyceride 3.000, Cyclomethicone 1.000, PPG stearyl ether 2.000, beeswax 2.000, stearic acid 1.500, sunflower oil 6.000, cetyl alc. 1.000, paraffin oil 4.000, wheat grass oil 1.000, and Et linoleate 7.500%, preservatives and perfumes qs and water to 100%.

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:31216 CAPLUS

DOCUMENT NUMBER: 136:90707

TITLE: Skin conditioning compositions containing compounds for mimicking the effect of retinoic acid on skin

INVENTOR(S): Granger, Stewart Paton; Scott, Ian Richard; Donovan, Robert Mark; Iobst-Teklits, Susanne; Licameli, Lisa

PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever NV; Hindustan Lever Limited

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002074	A2	20020110	WO 2001-EP7234	20010625
WO 2002002074	A3	20030612		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412788	A1	20020110	CA 2001-2412788	20010625
AU 2001079687	A5	20020114	AU 2001-79687	20010625
EP 1333800	A2	20030813	EP 2001-957886	20010625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012142	A	20031007	BR 2001-12142	20010625
JP 2004501952	T	20040122	JP 2002-506696	20010625
CN 1662216	A	20050831	CN 2001-814860	20010625
ZA 2002010288	A	20031219	ZA 2002-10288	20021219
US 2004043044	A1	20040304	US 2003-312659	20030811
PRIORITY APPLN. INFO.:			US 2000-215301P	P 20000630
			WO 2001-EP7234	W 20010625

AB A skin care product comprising about 0.001-10% of a retinoid, in combination with at least two retinoid boosters (0.0001-50%). Retinoid boosters are selected from fatty acid amides, carotenoids, flavonoids, non-cyclic fragrance compds., phospholipid analogs, ureas, phosphatidylcholines, phosphatidylethanolamines, sphingomyelins, fatty acids, linseed oil, elaidic acid, bifonazole, climbazole, clotrimazole, econazole, quercetin, coumarin, quinolines, isoquinolines, etc. A composition according to the invention is intended primarily as a product for topical application to human skin, especially as an agent for conditioning and smoothening the skin, and preventing or reducing the appearance of wrinkled or aged skin. In use, a small quantity of the composition is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or

a suitable device. For example, a synergistic inhibition of transglutaminase, as a marker of skin differentiation, was observed by retinol with various quaternary combinations of retinoid boosters, e.g., acetyl sphingosine, phosphatidylcholine, linoleic acid, and climbazole.

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:55520 CAPLUS
DOCUMENT NUMBER: 128:119667
TITLE: Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases
INVENTOR(S): Rephaeli, Ada; Nudelman, Abraham
PATENT ASSIGNEE(S): Bar-Ilan University, Israel; Kupat Holim Health Insurance Institution of the General Federation of Labor; Rephaeli, Ada
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800127	A1	19980108	WO 1997-US11452	19970701
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6040342	A	20000321	US 1996-674481	19960702
AU 9735880	A	19980121	AU 1997-35880	19970701
EP 927033	A1	19990707	EP 1997-932417	19970701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002514161	T	20020514	JP 1998-504403	19970701
PRIORITY APPLN. INFO.:				
			US 1996-674481	A 19960702
			US 1994-306422	A2 19940916
			US 1997-883219	A 19970626
			WO 1997-US11452	W 19970701

OTHER SOURCE(S): MARPAT 128:119667

AB This invention relates to novel retinoyloxy(substituted)alkylene butyrate compds. and pharmaceutical compns. containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment by comprising administering those compds., pharmaceutically-acceptable salts or prodrugs thereof to a patient. The compds. of the invention are also useful in methods of inhibiting histone deacetylase, ameliorating wrinkles, treating or ameliorating dermatol. disorders, inducing wound healing, treating cutaneous ulcers and treating gastrointestinal disorders. 13-Trans-retinoyloxymethyl butyrate was prepared and showed greater activity on the level of cell differentiation than either retinoic acid or butyric acid alone or a combination of the two.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:433716 CAPLUS
DOCUMENT NUMBER: 117:33716
TITLE: Liposomes comprising retinoids

INVENTOR(S): Trullas Cabanas, Carles Ramon; Pelejero Cabruja,
 Carles; Padros Morell, Esteve; Sabes Xamani, Manuel
 PATENT ASSIGNEE(S): Universitat Autonoma de Barcelona, Spain; Antonio Puig
 S.A.; Isdin S.A.
 SOURCE: Span., 18 pp.
 CODEN: SPXXAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Spanish
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
ES 2024381	A6	19920216	ES 1991-557	19910306
PRIORITY APPLN. INFO.:			ES 1991-557	19910306

AB Phospholipid liposomes, which incorporate retinoic acid
 or retinol palmitate, are prepared for cosmetic and
 dermatol. use. A film, made from a solution of egg phosphalidic acid
 and egg phosphatidylcholine (1:18) in CHCl₃, was treated with a
 solution of retinoic acid in Et₂O followed by
 resuspension in 50 mM phosphate buffer (pH 7) containing 100 mM KCl and
 liposome formation, as usual.

=> s L10 and L3
 L13 0 L10 AND L3